Alkem Laboratories Limited – FDA 483, May 1, 2026
The 483 report for Alkem Laboratories Limited details significant deficiencies in quality control, process validation, and complaint handling. The firm failed to thoroughly investigate Out of Specification (OOS) and Out of Trend (OOT) results, leading to delayed recalls and distribution of potentially substandard products. Additionally, issues with data integrity in QC testing, inadequate process validation, and failure to submit Field Alert Reports for repeated complaints were noted, indicating a lack of robust quality oversight.
ID · a0f0acc0-e24b-4a5a-8433-d86f0cae4bce
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.